Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a global pharmaceutical company engaged in the development and commercialization of innovative and high-quality drugs, focusing on the research and development of new drugs in the fields of anti-tumor, surgical drugs, autoimmune diseases, metabolic diseases and cardiovascular diseases. Innovation is the core development strategy. Hengrui has 12 innovative products and 1 cooperative innovative product marketed, more than 60 innovative candidates in the R&D stage, and more than 260 trials under clinical development around the world. Hengrui ranked 24th among the top 1,000 global pharma companies announced by the Torreya in 2021. We have been on the Pharma Exec’s annual listing of the top global pharmaceutical companies for the fourth consecutive year, rising from 47th in 2019 to 32nd in 2022.
